{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective from the specified list.", "method": "llm_batch", "batch_id": "batch_1_16484", "batch_size": 260, "batch_pos": 139, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "Neutral descriptions of plans and capabilities.", "method": "llm_batch", "batch_id": "batch_2_15836", "batch_size": 260, "batch_pos": 123, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "'plans to launch' and 'could respond' are about future/hypothetical actions.", "method": "llm_batch", "batch_id": "batch_3_17968", "batch_size": 260, "batch_pos": 61, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "No loaded rhetorical question present.", "method": "llm_batch", "batch_id": "batch_4_15412", "batch_size": 260, "batch_pos": 57, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports factual information about trial plans and capability ('respond very quickly') without explicit calming language or required tokens.", "method": "llm_batch", "batch_id": "batch_5_13160", "batch_size": 260, "batch_pos": 56, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
